NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 80 resultados LastUpdate Última actualización 01/02/2023 [08:40:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 4 nextPage   por página


MULTIPLE MYELOMA COMBINATION THERAPIES BASED ON PROTEIN TRANSLATION INHIBITORS AND IMMUNOMODULATORS

NºPublicación: US2023028293A1 26/01/2023

Solicitante:

SHERBENOU DANIEL [US]
WALKER ZACHARY [US]
IDLER BEAU [US]
UNIV COLORADO REGENTS [US]

WO_2021119023_A1

Resumen de: US2023028293A1

Multiple myeloma (MM) combination therapies based on protein translation inhibitors, immunomodulators, and bromodomain extra-terminal inhibitors. Methods are provided for treating multiple myeloma in a subject, including administering a therapeutically effective amount of at least one protein translation inhibitor and a therapeutically effective amount of at least one immunomodulatory drug (IMiD), administering a therapeutically effective amount of at least one protein translation inhibitor and a therapeutically effective amount of at least one BET inhibitor, and/or administering a therapeutically effective amount of at least one IMiD and a therapeutically effective amount of at least one BET inhibitor.

traducir

METHODS

NºPublicación: US2023027993A1 26/01/2023

Solicitante:

AUTOLUS LTD [GB]

Resumen de: US2023027993A1

The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.

traducir

CANCER TREATMENTS TARGETING CANCER STEM CELLS

NºPublicación: US2023023124A1 26/01/2023

Solicitante:

REMEDY PLAN INC [US]

JP_2022553865_PA

Resumen de: US2023023124A1

Disclosed are compounds, methods, compositions, uses, and kits that allow for treating cancer. In some embodiments, the compounds are used to treat diseases or disorders. The compounds may treat cancer by targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, lymphoma, liver cancer, endometrial cancer, leukemia, or multiple myeloma. Disclosed are compounds, methods, compositions, uses, and kits that may be used in regenerative medicine. The compounds utilized in the disclosure are of Formula (0) and (I).

traducir

N-ACYL-{4-(4-ARYL-PHENYL)SULFONYLMETHYLPIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE

NºPublicación: US2023022917A1 26/01/2023

Solicitante:

MODERN BIOSCIENCES LTD [GB]

JP_2022528799_A

Resumen de: US2023022917A1

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds of the following formula (collectively referred to herein as NASMP compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, e.g., multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, eosinophilic leukemia, glioblastoma, melanoma, ovarian cancer, chemotherapy resistant cancer, radiation resistant cancer, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, asthma, chronic obstructive pulmonary disease (COPD), Hidradenitis suppurativa, autoimmune hepatitis, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

traducir

IMMUNOTHERAPEUTIC COMPOSITIONS

NºPublicación: US2023022956A1 26/01/2023

Solicitante:

GLAXOSMITHKLINE BIOLOGICALS SA [BE]
VARIATION BIOTECHNOLOGIES INC [CA]

Resumen de: US2023022956A1

The present disclosure provides compositions and methods useful for treating Glioblastoma Multiforme (GBM) which comprise virus-like particles (VLPs) comprising murine leukemia virus (MLV) core proteins and the human cytomegalovirus epitopes, gB and pp65, formulated with an adjuvant comprising a saponin and a TLR4 agonist.

traducir

MODULATORS OF PROGRAMMED DEATH-LIGAND-1 AND/OR PROGRAMMED DEATH-LIGAND-2

NºPublicación: US2023029187A1 26/01/2023

Solicitante:

SOUTHERN RES INST [US]

AU_2020396100_PA

Resumen de: US2023029187A1

The present disclosure is concerned with dipeptide compounds for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanomas, gliomas, leukemias, lymphomas, chronic myeloproliferative disorders, myelodysplastic syndromes, myeloproliferative neoplasms, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

traducir

NEXT-GENERATION SEQUENCING DIAGNOSTIC PLATFORM AND RELATED METHODS

NºPublicación: US2023028058A1 26/01/2023

Solicitante:

OHIO STATE INNOVATION FOUNDATION [US]

WO_2021126896_A1

Resumen de: US2023028058A1

A system and method for accurate determination of sequence variants from noisy sequencing data, including single nucleotide variants and structural variants of the internal tandem duplication type. This system expands the utility of inexpensive sequencing instruments which stream relatively high-error output sequences in real time, such that they may be used in high-stakes contexts, such as clinical cancer care. An example application is Acute Myeloid Leukemia (AML), where healthcare providers may need to make decisions in hours, is provided.

traducir

INHIBITORS OF ENL/AF9 YEATS

NºPublicación: US2023027198A1 26/01/2023

Solicitante:

UNIV ROCKEFELLER [US]
BRIDGE MEDICINES LLC [US]

KR_20220129554_PA

Resumen de: US2023027198A1

Methods and compositions for treating leukemia are disclosed. Acylated 6-aminoindoles, acylated 6-aminopyrrolopyridines and acylated 3-aminopyrrolo[3,2-c]pyridazines of the following formulainhibit ENL/AF9 YEATS and are therefore useful for treating leukemia.

traducir

METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MANAGING CYTOPENIA

NºPublicación: US2023027184A1 26/01/2023

Solicitante:

GENENTECH INC [US]
ABBVIE INC [US]

US_2023000889_PA

Resumen de: US2023027184A1

Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein are methods of managing a cytopenia in such patient.

traducir

EP300/CBP INHIBITOR

NºPublicación: US2023027088A1 26/01/2023

Solicitante:

HINOVA PHARMACEUTICALS INC [CN]

JP_2022549471_PA

Resumen de: US2023027088A1

An EP300/CBP inhibitor, specifically provided is a compound as shown in formula I, or a deuterated product thereof, or a salt thereof, or a conformational isomer thereof, or a crystal form thereof, or a solvate thereof. The compound is highly selective for EP300/CBP, and can effectively inhibit the activity of EP300/CBP; in addition, the compound has an excellent inhibitory effect on various tumor cells including prostate cancer cells, leukemia cells, breast cancer cells and multiple myeloma cells. The compound has broad application prospects in the preparation of an EP300/CBP inhibitor, and drugs for preventing and/or treating tumors, myeloid hematopoietic stem/progenitor cells malignant disease, and regulating regulatory T cells.

traducir

METHODS

NºPublicación: US2023026111A1 26/01/2023

Solicitante:

AUTOLUS LTD [GB]

Resumen de: US2023026111A1

The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.

traducir

TREATMENT OF HEMATOLOGICAL MALIGNANCY

NºPublicación: WO2023002362A1 26/01/2023

Solicitante:

PFIZER [US]

Resumen de: WO2023002362A1

This invention relates to therapies useful for the treatment of hematological malignancies. In particular the invention relates to a method of treating acute myeloid leukemia (AML) in a patient in need thereof, wherein said patient is positive for at least one mutation of the FLT3 gene, said method comprising administering to said patient a smoothened inhibitor, or a pharmaceutically acceptable salt thereof, in combination with azacitidine, thereby treating said acute myeloid leukemia. The invention also relates to associated combination therapies, pharmaceutical compositions, pharmaceutical uses and kits.

traducir

NKG2D CAR CELLS EXPRESSING IL-18 FOR ADOPTIVE CELL THERAPY

NºPublicación: WO2023001774A1 26/01/2023

Solicitante:

CELYAD ONCOLOGY S A [BE]

Resumen de: WO2023001774A1

The present application relates to the field of immunotherapy, more particularly to the field of adoptive cell therapy (ACT). Here, NKG2D CAR expressing cells that also express IL-18 are proposed. Also proposed are polynucleotides, vectors encoding the NKG2D CAR and IL-18 and cells expressing both. These cells are particularly suitable for use in immunotherapy, including allogeneic therapy. The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. Further, strategies to treat diseases such as cancer using these cells are also provided. The engineered immune cells, such as T-cells or natural killer (NK) cells, expressing such CARs are suitable for treating lymphomas, multiple myeloma and leukemia, but other tumors can be treated as well, depending on the specificity of the CAR. Most notably, as expression and secretion of the pro-inflammatory cytokine I L-18 is beneficial to reducing the immunosuppressive effect of the tumor microenvironment, treatment of solid tumors is envisaged.

traducir

14-3-3 PROTEIN MODULATORS AS ANTITUMOR AGENTS

NºPublicación: WO2023001942A1 26/01/2023

Solicitante:

RAPPOSELLI SIMONA [IT]
GAUDIO EUGENIO [CH]
DAL PIAZ FABRIZIO [IT]

Resumen de: WO2023001942A1

The invention relates to a 2-oxoindole compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are, independently from each other, hydrogen,1H-imidazolyl, thienyl and 1-methyl-1H-imidazolyl, 2-methyl-1H-imidazolyl,2-aminopyridinyl, 1H-pyrazolyl, with the proviso that one of R1 and R2 is hydrogen; or R1 and R2 together form 9H-fluorene R3 is hydrogen, (C1-C3)alkyl, halogen or NO2; for use as a 14-3-3 protein modulator of a tumor selected from the group consisting of a lymphoma, chronic lymphocytic leukaemia (CLL), Ewing sarcoma, colon cancer, melanoma and anaplastic thyroid cancer (ATC). The invention relates also new 2-oxoindole compound of Formula (I) or a pharmaceutically acceptable salt thereof..

traducir

POLYSUBSTITUTED PURINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF

NºPublicación: WO2023000708A1 26/01/2023

Solicitante:

UNIV CHINA PHARMA [CN]

CN_113549076_A

Resumen de: WO2023000708A1

Disclosed are a polysubstituted purine compound as shown in formula (I), and a pharmaceutically acceptable salt thereof, a preparation method therefor and the use thereof. Also disclosed is that the compound has an obvious inhibitory effect on RNA adenosine deaminase 1 (ADAR1) and can be used for preventing and/or treating cancer or tumor-related diseases caused by abnormal activity of such enzymes, especially prostate cancer, leukemia, breast cancer, multiple myeloma, lung cancer, stomach cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer, human glioma and other diseases.

traducir

TARGETING DOT1L AND SMARCA4/2 FOR THE TREATMENT OF MLLR LEUKEMIA

NºPublicación: WO2023004283A1 26/01/2023

Solicitante:

DANA FARBER CANCER INST INC [US]

Resumen de: WO2023004283A1

Disclosed is a method of treating cancer with a compound that possesses degradation activity against SMARCA4/2 in combination with a DOT1L r inhibitor.

traducir

CXCR4 MODULATORS AND USES RELATED THERETO

NºPublicación: WO2023003862A1 26/01/2023

Solicitante:

UNIV EMORY [US]

Resumen de: WO2023003862A1

CXCR4 antagonists and pharmaceutical formulations thereof are disclosed. The compounds and pharmaceutical formulations disclosed herein can be used to antagonize the CXCR4 pathway for mobilizing stem cells or treating a condition, disorder, or disease associated with the CXCR4 pathway. Exemplary conditions, disorders, and diseases relevant to this disclosure include HIV infections, WHIM syndrome, Waldenström macroglobulinemia, chronic neutropenia, primary immune-deficiency, aplastic anemia, hypoplastic myelodysplastic syndrome, acute respiratory distress syndrome (ARDS), ankylosing spondylitis, autoimmune diseases, and cancers.

traducir

Dermatological Compositions and Methods of Treatment against Cutaneous T-Cell Lymphoma

NºPublicación: US2023024050A1 26/01/2023

Solicitante:

SOLIGENIX INC [US]

Resumen de: US2023024050A1

A method of treating CTCL comprising applying a combination of an effective amount of hypericin together with a form of visible light photodynamic therapy. Preferably, the effective amount of hypericin is an ointment comprising less than 1% hypericin. More preferably, the form of photodynamic therapy comprises an administration of escalating doses of visible light. Optionally, the escalating doses of visible light starts at about 5 J/cm2 and increases to a maximum dose of about 12 J/cm2.

traducir

CHEMICAL COMPOSITIONS AND METHODS OF USE

NºPublicación: US2023022417A1 26/01/2023

Solicitante:

LIQUID BIOPSY RES LLC [KN]

MX_2020000785_A

Resumen de: US2023022417A1

The present invention is directed to methods for detecting a plasma cell dyscrasia like myeloma or MGUS, methods for determining whether a plasma cell dyscrasiais stable or progressive, methods for determining a risk for disease relapse, and methods for determining a response by a subject having a plasma cell dyscrasia to a therapy.

traducir

METHODS

NºPublicación: US2023021548A1 26/01/2023

Solicitante:

AUTOLUS LTD [GB]

Resumen de: US2023021548A1

The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.

traducir

METHOD FOR DIAGNOSING CUTANEOUS T-CELL LYMPHOMA DISEASES

NºPublicación: US2023028910A1 26/01/2023

Solicitante:

SCAILYTE AG [CH]
UNIV ZUERICH [CH]

WO_2021129976_A1

Resumen de: US2023028910A1

The present invention relates to a method for diagnosing Sézary syndrome or mycosis fungoides in a subject. The present invention further relates to a method for determining the frequency of Sézary signature cells and/or mycosis fungoides cells in a sample. Further, the present invention relates to a computer-implemented method comprising a classifier algorithm to determine the frequency of Sézary signature cells and/or mycosis fungoides cells. In addition the present invention relates to a panel of biomarkers that can be used for the diagnosis of Sézary syndrome or mycosis fungoides.

traducir

COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA

NºPublicación: EP4121430A1 25/01/2023

Solicitante:

FLASH THERAPEUTTICS LLC [US]

TW_202200583_PA

Resumen de: WO2021184154A1

Provided herein are compounds for treating acute myeloid leukemia or inhibiting recurrence of acute myeloid leukemia and for inhibiting growth of and/or killing leukemic stem cells.

traducir

METHOD FOR DETECTING INDICATOR OF T-CELL LYMPHOMA AND UTILIZATION THEREOF

NºPublicación: EP4122494A1 25/01/2023

Solicitante:

MANDOM CORP [JP]
UNIV OSAKA [JP]
UNIV NAGOYA CITY PUBLIC UNIV CORP [JP]

KR_20220109441_A

Resumen de: EP4122494A1

The present invention provides a novel method for detecting an indicator of T cell lymphoma. The method for detecting an indicator of T cell lymphoma includes the step of detecting acetylated tubulin in a T cell that has been collected from a subject.

traducir

SOLID FORM OF PYRAZINE SUBSTITUTED NICOTINAMIDE, AND PREPARATION AND USE THEREOF

NºPublicación: EP4122928A1 25/01/2023

Solicitante:

SHENZHEN TARGETRX INC [CN]

CN_115413277_PA

Resumen de: EP4122928A1

Provided are a crystal form of a free base or a pharmaceutically acceptable salt of (R)-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-fluoropyrrolidin-1-yl)-5-(pyrazin-2-yl)nicotinamide (compound A), a preparation method therefor, and use of the compound in preparation of drugs for treating diseases mediated by Bcr-Abl kinase and mutants thereof, such as chronic granulocytic leukemia. Also provided are a method for preparing compound A, and a preparation containing compound A.

traducir

COMBINATION THERAPY FOR ACUTE MYELOID LEUKEMIA

Nº publicación: EP4121051A1 25/01/2023

Solicitante:

CELGENE CORP [US]

CN_115515582_PA

Resumen de: WO2021188387A1

Provided herein are methods of treatment of AML comprising administering 2-(4- chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)methyl)-2,2- difluoroacetamide or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a combination therapy.

traducir

Página1 de 4 nextPage por página

punteroimgVolver